BOULDER, COLORADO, September 1, 2011 – Siva Therapeutics is one of 30 emerging companies selected to present at the upcoming Rocky Mountain Life Science Investor and Partnering Conference in Denver from September 21st to 23rd, 2011. This event provides exposure for Siva to the local and national investment community, and will assist Siva in raising $2.2 million to take R&D operations through the next phase of work.“This financing round will enable us to file for, and obtain, an Investigational Device Exemption (IDE) from the FDA for our initial product offering,” said Len Pagliaro, PhD, CEO of Siva. “Entering the clinic with SivaRod™ therapy will be a major milestone in our development.”
About Siva Therapeutics Inc
Siva Therapeutics Inc is an early stage biotechnology company developing a photothermal device cancer therapy which uses heat to irreversibly damage solid tumor tissue. The heat is delivered to tumors by infrared light that is absorbed by gold nanoparticles and reemitted as heat. The size, shape, and surface chemistry of the particles target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Siva therapy is extremely safe, effective, and competitive in cost relative to surgery, chemotherapy, and radiation for cancer treatment. For more information please visit www.sivatherapeutics.com.
Media Contact: email@example.com
About the Rocky Mountain Life Science Investor & Partnering Conference
The RMLIPC, held every 2 years, is the premier life science investment and partnering conference for the 6 state Rocky Mountain region. For more information please visit: www.cobioscience.com/RMLIPC/RMLIPC_Home.